Quick Answer
Aprea Therapeutics, Inc. reported Common Stock Shares Outstanding of 8.19 million shares for the year ending 2025.
- Aprea Therapeutics, Inc. showed an increase of +49.5% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: 1.18 million shares | Q1 2020: 21.05 million shares | Q2 2020: 21.19 million shares | Q3 2020: 21.19 million shares | Q1 2021: 21.19 million shares | Q2 2021: 21.19 million shares | Q3 2021: 21.36 million shares | Q1 2022: 21.97 million shares | Q2 2022: 23.40 million shares | Q3 2022: 52.24 million shares | Q1 2023: 3.73 million shares | Q2 2023: 3.73 million shares | Q3 2023: 3.74 million shares | Q1 2024: 5.43 million shares | Q2 2024: 5.43 million shares | Q3 2024: 5.43 million shares | Q1 2025: 5.51 million shares | Q2 2025: 5.75 million shares | Q3 2025: 5.98 million shares.
- Over the full 8 years of available data (2018 to 2025), Aprea Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 609.1%.
- Historical annual values: Fiscal year 2025: 8.19 million shares | Fiscal year 2024: 5.48 million shares | Fiscal year 2023: 3.74 million shares | Fiscal year 2022: 2.66 million shares | Fiscal year 2021: 1.09 million shares | Fiscal year 2020: 21.19 million shares | Fiscal year 2019: 21.02 million shares | Fiscal year 2018: 1.16 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: